| In line with the annual report's theme, can management provide insights into the current... Read More | No Response |
| Can the independent directors help shareholders better understand the perspective that the results... Read More | Excluding out-licensing income, revenue increased 193% to $5.91 million in FY2023 from $2.02 million in FY2022... Read More |
| What are the critical milestones to obtain the “marketing authorisation” for Wafesil... Read More | |
| 1. Can management help shareholders understand the R&D budget set aside... Read More | |
| 1. The group report a revenue increase of 10% to $6.4 million in 2017... 2. The group has developed a new pipeline of nutraceutical products and... 3. As disclosed in the Corporate Governance Report (page 29), a sum of $130,000... Read More | 1. Revenue of Chemical Analysis increased 7% in FY2017 over FY2016. There... 2. We have identified 5 major regions in which we are exploring launching... 3. During FY2017, Centrum Capital had been engaged to provide... Read More |
| 1. New drug application is extremely costly and time consuming and shareholders may not be... 2. For the benefit of the current shareholders, the group must manage its expenses and cash... 3. In the Remuneration section in the Corporate Governance report (page 19), the... Read More | 1. Product: Wafermine™ Sublingual ketamine; PheoniX™ Sublingual... 2. Excluding share - based compensation, clinical t rials and... 3. RC commissioned Carrots Consulting to review the... Read More |
| Upcoming Q&A |
Your shortcut to staying informed
Subscribe now and get direct updates on Q&As and corporate action matters!
By clicking submit, you agree to our privacy statement, collection, use and/or disclosure of your
personal data to the extent necessary to provide you with this service.
